evidoria

← Back to browse

Good practice Imported

Yeda Research and Development — Weizmann Institute's Technology-Transfer Arm

Israel · Rehovot · See the Israel profile · See the Rehovot profile

Evidence: Descriptive / self-reported Top 42% 71/100 · Ask Evidence Copilot about this practice

Founded in 1959 as the Weizmann Institute's commercial arm, Yeda has generated over USD 2 billion in licensing revenue in a recent six-year period — some 80-90% from three inventions, led by the MS drug Copaxone — and returns about 40% of royalties to inventor-researchers.

2 USD billion
Licensing revenue (recent six-year period)
1 NIS billion
Historic royalty income
80-90 %
Share of royalty income from top three inventions
40 %
Royalty share returned to inventor-researchers
Yeda Research and Development — Weizmann Institute's Technology-Transfer Arm

Details

Maturity
Established
Promoter
Yeda Research and Development Co. Ltd. (commercial arm of the Weizmann Institute of Science)
Period
1959–present
Keywords
university technology transfer, pharmaceutical licensing, patent commercialization

Context

Yeda Research and Development Company was founded in 1959 as the commercial arm of the Weizmann Institute of Science in Rehovot, Israel. Its mandate is to license the Institute's scientific discoveries to industry and channel the proceeds back into research.

Objectives

Yeda's objective is to commercialise Weizmann Institute science through industry licensing deals, while returning a share of royalty income to the inventing researchers and reinvesting the remainder in the Institute.

Activities

Yeda licenses Institute discoveries to commercial partners, most notably the multiple sclerosis drugs Copaxone (licensed to Teva in 1987, FDA-approved 1996) and Rebif (licensed to Serono), and an NDS satellite-broadcast encryption system. It has also formed newer commercial ventures, such as Orchard Innovations with Deerfield.

Results

Yeda generated over USD 2 billion in licensing revenue during a recent six-year period and has historically earned more than NIS 1 billion in royalties, consistently placing among the world's top five academic institutions for royalty income. Roughly 80-90% of that income comes from just three inventions, and about 40% of royalty income is passed back to the inventing researchers.

Conclusions

Yeda is one of the world's oldest and most successful university technology-transfer offices, with a 65-plus-year track record. However, its revenue is a hit-driven model concentrated in a handful of blockbuster licences rather than a broad portfolio, a pattern that depends on a research institute of Weizmann's calibre and is difficult to replicate deliberately.

Implementation
Indicative cost
High (€500k–€5M) — Self-funded through royalty and licensing income; no public subsidy figures reported.
Time to results
Long (> 3 years) — Operating continuously since 1959 (66 years by 2026).
Staffing & skills
Yeda Research and Development Co. Ltd. staff (Weizmann Institute's tech-transfer company)

Conditions for success

  • A high-calibre research institute producing blockbuster-potential inventions (e.g., Weizmann Institute)
  • Long-term operation to allow patents to mature into licensing deals
  • Royalty-sharing incentive returning roughly 40% back to inventors

Common failure modes

  • Revenue concentration risk: 80-90% of income depends on just three inventions
  • Hit-driven model that is hard to replicate deliberately without a similarly strong research base

Where it fits

Governance type
university/research-institute technology-transfer company
Scale
national/international licensing operations
Income level
high-income

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful